Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ ...
Pfizer Inc. (NYSE:PFE) revealed results from the Phase 3 BREAKWATER trial evaluating Braftovi (encorafenib) in combination ...
Pfizer’s BREAKWATER trial of Braftovi combo regimen demonstrates improved response in patients with BRAF V600E-mutant metastatic colorectal cancer: New York Tuesday, January 28, ...
Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them ...
US pharma giant Pfizer on Saturday announced positive results from the Phase III BREAKWATER trial evaluating its Braftovi ...
3d
Pfizer Inc. (PFE) announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI (encorafenib) in combination with ...
Pfizer has shared positive results from a late-stage study of its Braftovi (encorafenib) combination in BRAF V600E-mutant ...
Pfizer (PFE) colorectal cancer therapy Braftovi as part of a drug combo indicates a favorable objective response rate in a ...
Pfizer Inc. today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, ...
Beloved New Zealand DJ Andyheartthrob, real name Andrea Orani, has died following a battle with cancer. Her manager, ...
Tired of random DMs, awkward intros, or shallow connections? Viberse, the social app for connecting with people through sharing glimpses of life, introduces Tango?a fun, daily mission designed to help ...
First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback